The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Conversation with The Cancer Letter

NCI’s Penberthy: We may be seeing some impact of treatment in lung cancer mortality, but we need more data

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

If the mortality rate for lung cancer is starting to fall of a cliff in part because of treatment effect—contributing to more than a third of the 2.2% decline in overall cancer mortality from 2016 to 2017—is that signal showing up on the radar of NCI’s Surveillance, Epidemiology, and End Results (SEER) Program?

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Matthew Bin Han Ong
Matthew Bin Han Ong
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Patricio Polanco named chief of surgical oncology and surgeon-in-chief at Atrium Health Levine Cancer

Patricio M. Polanco, a surgical oncologist specializing in hepato-pancreato-biliary malignancies and minimally invasive and robotic liver and pancreas surgery, has joined Atrium Health as division chief of surgical oncology, surgeon-in-chief for Atrium Health Levine Cancer in Charlotte, North Carolina and inaugural Richard L. White Jr. Endowed Professor of Surgery at Wake Forest University School of Medicine. 
Byline
Matthew Bin Han Ong
Matthew Bin Han Ong
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account